Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01857531 · ClinicalTrials.gov registry record · Phase 2
Proof-Of-Concept Investigation With a Neurosteroid Analog (Ganaxolone) as a Smoking Cessation Candidate
A Phase 2 study of Smoking Cessation, sponsored by Jed E. Rose.
- Completed
- Registry status
- Phase 2
- Development phase
- 36
- Enrollment target
- 4
- Study locations
NCT01857531 is a Phase 2 study of Smoking Cessation that has completed, run by Jed E. Rose. The registered enrollment target is 36 participants, below the 475-participant average among 188 other Smoking Cessation trials with a reported enrollment target (92% lower). The trial reports 4 study locations across 1 state.
The verdict
NCT01857531, a Phase 2 study of Smoking Cessation, has completed, sponsored by Jed E. Rose.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 36 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this research study is to evaluate whether the investigational drug ganaxolone can help smokers quit smoking. Ganaxolone is a drug that has been investigated (in other research studies) for the treatment of seizures and migraines. This drug is considered investigational in the US.
Conditions Studied
Interventions
- DRUG Nicotine Patch
- DRUG Ganaxolone
Study Locations (4)
North Carolina
- Duke Center for Smoking Cessation - Charlotte
- Duke Center for Smoking Cessation - Durham
- Duke Center for Smoking Cessation - Raleigh
- Duke Center for Smoking Cessation - Winston-Salem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2013-06 |
| Est. Completion | 2014-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01857531
The ClinicalTrials.gov registry entry for NCT01857531 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 475-participant average among 188 other Smoking Cessation trials with a reported enrollment target (92% lower). The listed sponsor is Jed E. Rose, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Smoking Cessation appearing as the primary indexed condition, and to 2 interventions - of which Nicotine Patch is the first listed.
NCT01857531 reports 4 study locations spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT01857531 about?
NCT01857531 is a clinical study titled "Proof-Of-Concept Investigation With a Neurosteroid Analog (Ganaxolone) as a Smoking Cessation Candidate". The purpose of this research study is to evaluate whether the investigational drug ganaxolone can help smokers quit smoking. Ganaxolone is a drug that has been investigated (in other research studies) for the treatment of seizures and migraines. This drug is considered investigational in the US.
What is the current status of trial NCT01857531?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2013-06. Estimated completion is 2014-02.
What conditions does trial NCT01857531 study?
This clinical trial studies the following conditions: Smoking Cessation.
What interventions are being tested in trial NCT01857531?
The interventions under investigation include: Nicotine Patch (DRUG), Ganaxolone (DRUG).
Who is sponsoring clinical trial NCT01857531?
This trial is sponsored by Jed E. Rose, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01857531 being conducted?
This trial has 4 study locations across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Smoking Cessation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Examining the Effects of Cytisinicline on Neural Substrates of Cigarette Cue-reactivity
RECRUITING · Phase 2
-
Smoking Cessation Pharmacotherapy-Nurse Practitioner Led Tobacco Treatment Team Study
RECRUITING · Phase 2
-
Treating Smokers With Mental Illness
COMPLETED · Phase 2
-
Suvorexant to Reduce Symptoms of Nicotine Use
COMPLETED · Phase 2
-
Pharmacogenetics, Emotional Reactivity and Smoking
COMPLETED · Phase 2
-
Provoked Craving Relief Study by NRT
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.